UK: Medical cannabis treatments in UK to be limited over doctors’ fears and lack of regulation despite new law

Exclusive: ‘It’s frustrating because these families have tried everything available to them but their doctors still wont prescribe medical cannabis,’ says Hannah Deacon


Only a minority of patients who stand to benefit from potentially life-changing medicinal cannabis prescriptions will be able to access it after laws change on 1 November, experts have warned.

Despite the potential to help thousands with conditions like epilepsy, multiple sclerosis and nausea from cancer treatment, The Independent has learned that most doctors are so far refusing to prescribe.


Medicinal cannabis prescriptions have already been approved for Alfie Dingleyand Billy Caldwell, two boys with rare forms of epilepsy whose parents’ campaigns were instrumental in changing legislation.




But other families in a similar position who have applied for licenses through a temporary approval panel are being “frustrated” by flat refusals from their doctors.


Alfie Dingley’s mother, Hannah Deacon, helped coordinate a public campaign to access the cannabis extract helping Alfie “live a normal life” and now works as an ambassador for cannabis campaign group End Our Pain.

She has been working with 16 families who have been trying to access cannabis for their epileptic children, but in all but two cases the families were refused by their doctor when they asked to try the treatment, while the families who had their paediatrician’s support were rejected by the temporary approval panel and told to try a medicine not currently licensed in the UK.



“It’s very frustrating because all the families are coming back to me saying ‘my doctor still says they won’t do it’,” Ms Deacon added. “They have all tried everything available to them, and their children are still very, very sick. So they’re prime candidates for trying cannabis medicine – it might not work for them like it does for Alfie, but when you’re in that situation you just need to try everything.”

The cannabis treatment used by Alfie is a “whole plant extract” which contains dozens of cannabinoids and chemicals called terpenes. Many patients report greater benefits from these extracts than cannabis-derived pharmaceutical products which contain just one or two cannabinoids, but they cannot be tested or licensed in the same way as conventional medicines.


This could pose legal problems for doctors.

“If a neurologist prescribed private, medicinal cannabis for a multiple sclerosis symptom, and some side effect or harm happens to the patient, even if it’s mild, then legally that neurologist is in great difficulty if there is no license for that [cannabis preparation],” Dr Waqar Rashid, a consultant neurologist at St George’s Hospital specialising in MS told The Independent.

In Dr Rashid’s view, the only system that could protect doctors and their patients would be to prescribe through a registered medical trial – potentially limiting numbers and increasing costs.

“To say people can prescribe this from November is not correct, really,” he said. “Even with the best will in the world we’re looking at very selective numbers of neurologists prescribing this and it would need the infrastructure to support it.”



Other doctors are looking to expand this base of understanding among doctors and hope to make it more mainstream in time.

“The big barrier to prescription will be the doctors really,” Professor Mike Barnes, a neurologist and consultant on medicinal cannabis who helped secure Alfie Dingley’s prescription. At the minute it’s a blanket ‘no’ where families have applied. One said ‘it’s a passing fad’ but others have said we’re not doing it because there’s no evidence from double-blinded, placebo-controlled trials [used for licensing other drugs].”

“That’s sort of understandable in one way[…] but you have to remember these children continue to be on many different anti-convulsants, and their epilepsy is not controlled. You have to take into account the side effects of that existing medication and damage to the developing brain of continued seizures.”



Professor Barnes has established the Medical Cannabis Clinicians Society, which has already enlisted around 60 doctors for its inaugural event next month and will include training on key areas like dosage and side effects.

Over time he hopes this will give a “small core” of doctors who can help establish cannabis treatment in their hospitals and specialities. They will also be a way of overcoming the reservations of cash-strapped NHS clinical commissioning groups which will be required to fund the treatments and are also stuck without guidance from the government.

Home Office legislation reclassified cannabis and set out it should only be prescribed by specialist doctors – rather than GPs. Detail of how this is regulated and funded is due from the Department of Health and Social Care before 1 November – but has yet to be released leaving the health service in the dark.


Meanwhile, patient groups and charities are already being approached by patients enquiring about the potential of cannabis treatment, and have urged the government not to allow delays that could penalise patients who can’t afford to go private.




“This law change is a landmark moment and could have a huge impact for people with multiple sclerosis,” Genevieve Edwards, director of external affairs at the MS Society, said.

“More than 100,000 people in the UK live with this often painful and exhausting condition and cannabis for medicinal use could help roughly one in 10 of them get relief from pain and muscle spasms.”

“However, we’re concerned that people won’t be able to access cannabis for medicinal use on a wide scale from 1 November. It is critical specialist doctors have the support and information they need to prescribe in a fair and timely way on the NHS.”

The Independent approached the Department of Health and NHS England for comment on these issues but both groups declined to comment in advance of the guidance.



Link –

Namaste Provides Update on UK Medical Cannabis Strategy

Namaste Technologies Inc. (“Namaste” or the “Company”) (TSXV: N), (FRANKFURT: M5BQ), (OTCMKTS: NXTTF) is pleased to provide an update for investors on its strategy to launch medical cannabis sales within the UK market. Namaste operates a global e-commerce platform which sells cannabis ancillary products in over 20 countries around the globe. One of the Company’s largest consumer databases lies in the UK, with over 500,000 customers. With the impending roll-out of medical cannabis in the UK market, Namaste is well positioned to leverage its database along with its telemedicine application and potential acquisition of Access Fulfilment Ltd. (“Access Fulfilment”) to enter directly into medical cannabis sales in the UK. The Company’s strategy includes medical cannabis importation, telemedicine and distribution.

Subject to compliance with UK federal regulations, the Company will be launching a UK version of its innovative telemedicine application, NamasteMD, which has been designed to provide patient consolations for the purposes of acquiring medical cannabis prescriptions, and is available in the Apple Store, on Android and on desktop at The Company plans on submitting NamasteMD to the UK App Store and for Android in November 2018. The Company is active in securing strategic relationships with clinics and specialist healthcare practitioners that will provide resources to facilitate patient onboarding in the most effective manner possible.

Further to the Company’s September 13th, 2018 news release, Namaste has entered into a binding terms sheet (the “Terms Sheet”), to acquire all of the issued and outstanding shares of UK-based Access Fulfilment Ltd. (“Access Fulfilment”). Access Fulfillment operates a 30,000 square-foot distribution facility in the UK and holds a Wholesale Distribution Authorization (Human) License issued by the Medicines and Healthcare Products Regulatory Agency (“MHRA”) which allows Access Fulfillment to distribute pharmaceutical products throughout the UK. The Company intends on closing of the acquisition and is undergoing due diligence and are actively engaged with Access Fulfilment to supply an amendment to their license to allow for distribution of medical cannabis products.

The Company is pleased to have launched sales through its wholly-owned subsidiary, Cannmart Inc. (“Cannmart”), which is the first medical cannabis “sales-only” license in Canada which has been issued to a non-cultivator. The Company has secured supply channels for Cannmart and has also acquired future supply through strategic agreements and investments offering a Right of First Refusal (“ROFR”) on inventory through several cultivators that will guarantee supply to Cannmart now and in the future. The Company has begun the process of its application for Good Manufacturing Practice (“GMP”) certification for Cannmart, and as such, will intend on exporting cannabis from the Canadian market to the UK directly. Namaste is actively pursuing new supply channels in Canada and abroad which will support the Company’s anticipated demand for medical cannabis in the UK and in other emerging markets like Australia, where the Company maintains large databases of cannabis consumers.

Tales of THC Terror

Tales of THC Terror

Generations of weed smokers have been entertained and astounded by absurd propaganda pieces alleging impossible scenarios all based around some ill-fated run-in with the Devil’s Lettuce, cannabis. From insanity to cannibalism to death, every last horrible thing has been blamed on weed. Given that today is Halloween, let’s get one of the biggest whoppers out of the way first.


Every October, news outlets run articles cautioning against suspicious ne’er-do-wells creeping about, handing out drug-laced candy to the kiddies. In the 1970s it was cocaine, in the 1990s it was crack, and today it is weed. Parents are drilled to pore over any candy or treats given to children, to make sure everything is perfectly safe. Hospitals even offer to X-ray candy for free to look for foreign objects. But like all of the other horrific items people have supposedly stuffed into sweet treats — razor blades, poisons, independent thoughts — there is absolutely no record in any police department in the country of a single incident. And I mean, can I be super real for a moment? Edibles are expensive. Who is blowing their stash on some kid who can’t even comprehend the difference between an indoor and outdoor grow?


One of the classic stories is about Dr. James Munch, who was a pharmacologist, and just happened to be a really good friend of Harry J. Anslinger, the chief honcho of the U.S. Federal Bureau of Narcotics from 1930 to 1962. Anslinger would call on Munch to testify to the perils of the “devil weed.” This motherfucker right here declared — under oath! — that “after two puffs on a marijuana cigarette, I was turned into a bat.” This bullshit opened the door for several murderers to avoid sentencing by claiming to be under the psychosis-inducing effects of weed. Anslinger kept Munch on the bench after that one.


Back in 2014, police chief Michael Pristoop was testifying against legalization in his home state of Maryland. Citing a chilling statistic from Colorado’s experience with legalization, he dropped this truth-bomb: “I remember the first day it was decriminalized, there were 37 deaths.” This was followed by the deafening sound of every jaw in the room hitting the floor because homeboy was quoting a story that originated on a satire website. A senator in the room tried to correct him, but the chief was having none of that. “If it was a misquote, then I’ll stand behind the mistake,” said Pristoop. “But I’m holding onto the information I was provided.” This guy gets to carry a gun, btw.

As it turns out, no one has ever overdosed and died from cannabis consumption. Anywhere. Ever.


One of the longest standing fables around weed is the subject of flashbacks. Just like LSD, people have claimed that the sudden release of THC from fat cells being rapidly broken down, like during exercise, sex, or crash dieting, results in either a flashback or showing up positive during a drug test. In fact, this myth is so pervasive that in 2009, a professor from Australia based a paper around the idea and the British Journal of Pharmacology published it. However, it’s almost impossible for a cell to hold enough THC to show up on a test. These days, more and more doctors and physiologists are coming forward to debunk this myth once and for all. They suggest that the momentary high is coming from naturally occurring drugs like endorphins and dopamine, and most importantly, anandamide, which fits into the same receptors in our brains as THC. Sorry, no free high for you. And that’s the scariest story of all.


No ‘reefer madness’ following legalization in Kamloops

No ‘reefer madness’ following legalization in Kamloops


Fears of increased crime and bylaw complaints in Kamloops following the legalization of cannabis appear to have been put to rest.


Kamloops Mayor Ken Christian questioned the RCMP detachment’s superintendent about any increases in crime since cannabis was legalized on Oct. 17, and the first government-run dispensary in the province opened in Kamloops.


“There was speculation that crime would be rampant and that we were going to have reefer madness in Kamloops,” Christian said to the city’s Officer in Charge at a Community Safety Meeting on Oct. 29. “Has there been any noticeable increase in crimes, in relation to recreational cannabis?”


Kamloops RCMP Supt. Syd Lecky answered with a firm ‘No’, and explained to reporters following the meeting that not much has changed within the city or the detachment since legalization.


“We knew what was coming, we’ve had processes in place to address impaired driving whether it be by alcohol or by drugs. It really was almost a seamless transition for us,” said Lecky. “Initially, there was people smoking in public and that sort of thing but until the bylaws are in place and whatever processes, (there’s) really not much of a concern for us.”


There are still illegal marijuana dispensaries operating in the city, although Lecky wouldn’t confirm how many were still up and running. He said the detachment is taking a slightly relaxed approach to these businesses, but reiterated that RCMP would act if complaints were made.


“We’ll wait to… take our lead from the provincial agency that’s going to be looking after that, but once they’ve done their part — I’m not going to say we’ll never react, but we’ll react as needed and when needed, and we’ll take our lead in part from what’s happening elsewhere,” Lecky said. “There’s community interest, there’s our mayor and council, and our own intelligence too. So it all depends on what’s happening. Not everyone’s playing by the right rules, either.”


Blood-sucking Sand Flies Love Munching on Marijuana


Blood-sucking Sand Flies Love Munching on Marijuana

When they’re not sucking the blood of animals, sand flies have a fondness for munching on the marijuana plant (Cannabis sativa), new research suggests.


An international team of scientists found that in proportion to its abundance, Cannabis sativa was consumed by sand flies much more frequently than expected, suggesting it was highly attractive to the insects.According to a paper published in the journal Proceedings of the National Academy of Sciences, the findings could have implications for controlling the spread of diseases that sand flies—which are found across the globe—transmit.


Female sand flies suck the blood of vertebrates in order to provide the necessary protein for their eggs to mature. During this process, the flies can transmit pathogens to humans, causing diseases such as bartonellosis and leishmaniasis—which infect between 4 million and 12 million people around the world, resulting in 20,000 to 50,000 deaths annually.In addition to sucking on blood, both females and males eat sugars from plants as a source of energy.


These meals may come in the form of sugary solutions such as nectar or plant sap—which the flies can access by piercing leaves and stems with their needle-like mouthparts.As a result, the availability of their preferred plants can influence where and when sand flies are distributed.


This, consequently, helps researchers to identify areas that are at higher risk of infection from the diseases they transmit. Wild cannabis plants, near Bura, Kazakhstan David Poché For the study—led by Ibrahim Abbasia from the Institute for Medical Research Israel-Canada and the Hebrew University of Jerusalem—the researchers used next-generation gene-sequencing techniques to determine the types of plant meals that the flies were eating.The team trapped sand flies in five unique regions—across Brazil, Ethiopia, Kazakhstan and Israel/Palestine—and tested them, finding that they ingested a variety of plants.


According to the analysis, the most commonly consumed plant in four of the five sites was Cannabis sativa, despite its apparent lack of abundance in the areas studied.While the authors could only speculate as to why the sand flies had such a preference for eating marijuana plants, the findings could provide a potential new avenue for controling sand fly populations and mitigating the spread of disease.“A novel approach for controlling blood-sucking mosquitoes and sand flies exploits their plant feeding habit by utilizing attractive toxic sugar baits [ATSBs] that emit olfactory cues to attract sand flies and mosquitoes,” the authors wrote in the study. By adding cannabis extracts to these ATSBs, researchers could improve their effectiveness for controlling disease-spreading insect populations, the authors suggest.




Nova Scotia’s first licensed cannabis brand called SKOSHA

Nova Scotia’s first licensed cannabis brand called SKOSHA


WENTWORTH, N.S. —  A cannabis producer in Wentworth has announced the introduction of the province’s first licensed marijuana for recreational consumption.


Breathing Green Solutions has launched a recreational cannabis brand called SKOSHA.


“There’s no denying that Nova Scotians have a taste for local,” said Joe Sanford, operations manager and co-founder at Breathing Green Solutions.

“In bringing the SKOSHA brand to market, we want to give local consumers a cannabis option that is unmistakably Nova Scotian,” he said in a news release. “We’re excited to offer recreational consumers distinctly local cannabis options which follow in our province’s tradition of creating incredible local products.”


Breathing Green Solutions, a modern facility located in Wentworth Valley, recently became Nova Scotia’s first licensed cannabis producer.


None of the cannabis brands currently sold though Nova Scotia Liquor Commission outlets are produced in Nova Scotia.


Sanford said an announcement is planned for later this week as to where and when SKOSHA products will be available.


He said the SKOSHA brand emphasizes the hyperlocal nature of its handcrafted cannabis and the homegrown brand aims to resonate with recreational consumers who prefer to buy local.

The SKOSHA brand is the product of five years of “hard work by the Breathing Green Solutions team,” he said, and the first two strains that will be available under that name echo that Nova Scotian theme with a nod to the weather.


One strain is called Nor’Easter, a sativa-dominant hybrid THC strain while a second is called Shelter, which is described as a milder, indica-dominant hybrid strain with a nearly balanced THC-to-CBD ratio.

“For the first time, recreational consumers in Nova Scotia will be able to experience the difference that handcrafted, locally grown cannabis products can make,” the release said.


Nor’Easter is a sativa-dominant hybrid THC strain named in honour of the powerful storms Atlantic Canada is famous for. With primary terpenes of pinene, caryophyllene and limonene, Nor’Easter expresses aromas of pine needles, spice and citrus.

Shelter is a milder, indica-dominant hybrid strain with a nearly balanced THC-to-CBD ratio. Shelter’s unique terpene profile is dominated by guaiol and limonene, delivering a piney, citrusy aroma with undertones of rose and wood.


Please allow small farmers to benefit from ganja industry, says senator

Please allow small farmers to benefit from ganja industry, says senator


GOVERNMENT Senator Kerensia Morrison is calling on the Government to ensure that small farmers and the little man are not left out of the emerging ganja/cannabis industry.


“Perhaps the most critical point that I am going to make on this issue is that our small farmers, the little man, must not be left behind on this lucrative ganja ship,” Senator Morrison said as she opened the 2018/19 State of the Nation Debate in the Senate last Friday.


“It is very important that ordinary Jamaicans are not marginalised as we capitalise on the benefits of the ‘Green Gold’ that is the emerging medicinal ganja industry. Small traditional ganja farmers, the same ones who were persecuted and who bore the full brunt of the law, the same ones who first believed in the power of the herb, the same ones who were seen as worthless and as criminals, must not be pushed aside by those who never believed in it, but who today have the big bucks to get into the industry,” she said.


“The small farmer, the bushman, the Maroons, the Kumina practitioners, the Rastas who have long considered the holy herb as sacrament, must not be alienated now that the world has embraced it. They too must be the face of the reward from cannabis. We ought to create a niche for them, include them in the discussions, include them in a regulated framework where they can be trained in standards and monitored as per the requirements of the law and licensing authority.


“Include them; it would be a travesty if they were left out and the face of cannabis, the face of ganja for medicinal use is the face of others who did not believe. All must benefit,” she added.


Morrison expressed two perspectives on the issue as she opened her presentation. The first being that the country has a responsibility to protect the vulnerable from the effects of the drug.


“We cannot discount the possibility that many of our youths will see this as the opportunity to light up. One may argue that cannabis was always accessible to a youth who wanted to smoke and this may not see a change in statistics,” she said.



However, she said that even if that view is not be true, the country should exercise due care, even as it looks at “the big dollars” raked in by other countries which have gone all the way to legalise the drug’s recreational use, to not only focus on the gains, but also the socio-economic value and the contingencies to deal with the issues that may emerge.


She said that her other perspective was that Jamaica has the ability to put mechanisms in place that would drive legislation to legalise it.


“We have cannabis that the world craves therefore, and this is what I am supporting, for its promising implications for medicine. The world needs to see Jamaica as an authority and leader in medical research in cannabis, for treating and relieving pain in cancer patients, for glaucoma, for epileptic fit, for victims of opioid, the implications for ganja as an effective treatment are excellent,” she stated.


Senator Morrison also noted that, for a long time, Jamaica has been viewed negatively for the illicit ganja trade. However, she said that these latest developments provide an opportunity to change the country’s reputation into one that is positive, by becoming a leading voice in medical research and its use in pharmaceuticals.


“Set up research centres here in Jamaica, let the world come here — not to ‘get high’ but for medical treatment and to discover more about the weed,” she said.


The State of the Nation Debate — the main annual debate in the Senate — is expected to continue when the Senate meets again, which is likely on Friday.


Why I Use Cannabis To Help Treat My Adult ADHD

Why I Use Cannabis To Help Treat My Adult ADHD

Certain cannabinoids and terpenes have motivational properties

ADHD is a quite complicated bit of neurodiversity. Sometimes you’re an attention superhero, focused as a spotlight, bingeing the grandest projects into the wee hours of the morning. Other times, you’re a mopey, distracted mess, unable to do the most basic of tasks for days or weeks on end. Though it’s a complex life that isn’t easy, it’s got its perks — and fervent and seemingly limitless creativity can be among them.


ADHD manifests in symptoms of hyperfocus, inability to focus, executive functioning issues, and sometimes irate behavior and mood swings. People who have this disorder will go to great lengths to counteract the negative effects, some self-cope unknowingly for years before ever receiving a diagnosis, especially women.


Like some others with ADHD, I use cannabis to medicate, but as testing and peer reviewed research is scarce in these early days of innovation, anecdotal evidence is the only peek behind the curtain of those of us with such brains. Cannabis is decidedly not a cure-all for this condition, but for some, its effects can provide a stimulant free adjustment of both attitude and attention.


I asked cannabis consultant and researcher Emma Chasen what she thinks about the possibility of cannabis assisting those with ADHD. She says, “People with ADHD are more likely to consume cannabis. Scientists are not quite sure why this is, however, we do know that certain cannabinoids and terpenes have motivational properties. And the motivational properties of these compounds are actually influenced by the hyperactive brain.


“For example, there is anecdotal evidence to support that THC and a terpene commonly found in the haze varieties – terpinolene – produce a very motivating, focused experience for those with ADHD & hyperactive, inattentive tendencies. This is in direct contrast to the anxiety-inducing, overwhelming experience that THC and terpinolene can induce for people who do not have symptoms of ADHD.


“More research is needed to elucidate the synergistic properties of cannabinoids and terpenes as they relate to symptom relief, especially when discussing diagnoses like ADHD. However, it seems that cannabis can help as long as the cannabinoids and terpenes are in the optimal ratios/concentrations.”


Chasen and other researchers believe that the various concentrations in different cannabis phenotypes are under researched and that when we understand every molecule in the equation, we will be closer to developing individualized medicine with cannabis.

Bloodsucking flies with a taste for cannabis plants identified by scientists

Disease-spreading insects could be controlled using extracts from illegal shrubs

Flies known to carry diseases to humans appear to have an unusual taste for cannabis – a habit that may help scientists target these pests.


Sand flies suck human blood, and in doing so they can transmit unpleasant infections such as the ulcer-causing leishmaniasis.


They also need to drink sugary sap in order to survive, and a group of scientists set out to find which plants these tiny creatures favoured in order to better understand their movements.


To their surprise, they found that in sites from Brazil to the Middle East, these flies appeared to be seeking out cannabis plants.


Due to the illegality of cannabis in all the countries where the scientists were working, they did not come across the plants in the wild except for a few shrubs in Kazakhstan, where they grow naturally.


The fact that cannabis was the most commonly consumed plant for sand flies trapped in four of the five regions they visited therefore suggested that the insects were actively seeking these plants out.


“We conclude that cannabis comprised but a small fraction of the available sugar sources in any particular habitat and that its ample representation among sand fly plant meals signifies bona fide attraction,” the scientists wrote in their Proceedings of the National Academy of Sciences paper.


After trapping insects across five international sites, the team led by professor Alon Warburg from the Hebrew University of Jerusalem identified which plants they had been eating by extracting DNA from inside the flies.


As insects seem to lack receptors to detect and respond to the active ingredients in cannabis, the scientists were unsure what benefit the flies were taking from its sap besides a sugary meal.


However, they noted that sugar baits are being used as a means to catch and control mosquitoes and other insects that carry deadly diseases. 


Cannabis could therefore be used to produce sand fly-specific baits to control their numbers in problem regions.

The general public is almost twice as likely to support the legalisation of cannabis in the UK than they are to oppose.


Key Findings from Volteface’s Cannabis Poll


2018 has been a significant year for cannabis policy, with the Billy Caldwell campaign kicking off in June, The Children’s Inquiry published in September and Canada recently becoming the first G7 country to legalise cannabis for recreational use.

With access to medical cannabis over three days away, Volteface and the Centre for Medicinal Cannabis commissioned Populus to find out where public opinion now sits.


Recreational Cannabis

  • The general public is almost twice as likely to support the legalisation of cannabis in the UK than they are to oppose. 59% strongly support or tend to support the legalisation of cannabis, compared to 31% who strongly oppose or tend to oppose. There has been a 37% increase in support since the May 2018 YouGov survey was conducted (from 43% to 59%), and accordingly opposition has fallen by 32% (from 41% to 31%).
  • Support for the legalisation of cannabis in the UK is strongest amongst younger age groups (68% SUM: support amongst 18-24 year olds) and falls with age (49% SUM: support amongst 65+ year olds).
    65% of the British public think that our cannabis laws should be reformed. 40% support legalisation and a quarter (25%) call for the decriminalisation- where the sale and possession of cannabis should remain illegal but be regarded as a minor offence, such as parking in the wrong place, rather than a criminal offence
  • Only one third of the British population (34%) think the sale and possession of cannabis should remain a criminal offence. Older age groups are most likely to rank the continuation of currently policy as their preferred option (39% of 55-64 year olds and 43% of 65+s).


Medical Cannabis

  • The UK public is open to consuming cannabis as a medicine if prescribed to them by their doctor – 76% would be willing to do so, and this level of agreement is fairly consistent across demographic groups.
  • 13% plan to ask their doctor or healthcare provider about accessing cannabis medicines when these products become legal to prescribe on the NHS. Younger respondents (18-24 year olds) are slightly more likely than the rest of the population to plan to do this (18% and 19% respectively). That’s around 6.7million people planning to ask their doctor about cannabis.



  • 15% of the population say they have consumed cannabis at some point in their lives– and this figure is highest among 18-24 year olds (at 28%) and lowest among 65+ year olds (7%).

Your message has been successfully sent.
Oops! Something went wrong.

Get in touch

If you wish to enquire about anything, or just say hi, please fill in the form opposite, or email us on: